Jump to content
Sclero Forums

Search the Community

Showing results for tags 'dmards'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 7 results

  1. The risk of malignancy and its incidence in early rheumatoid arthritis (RA) patients treated with biologic DMARDs. In early RA patients, bDMARD use decreases the overall risk of developing malignancies; however, it does not affect the risk of developing hematologic malignancies. PubMed, Arthritis Res Ther, 2017 Dec 15;19(1):277. (Also see DMARDs and Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Dosing down and then discontinuing biologic therapy (bDMARD) in rheumatoid arthritis (RA): a review of the literature. In patients who have achieved low disease activity or remission, down–titration and discontinuation of bDMARD therapy may be attempted, with careful monitoring. PubMed, Int J rheumatologist Dis, 12/04/2017. (Also see Treatments for Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Metabolic and cardiovascular benefits of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA) : a systematic review and meta–analysis. HCQ may benefit the metabolic profile and to a lesser extent cardiovascular events in patients with RA, which suggests its usefulness combined with other conventional synthetic disease–modifying antirheumatic drugs. PubMed, Ann rheumatologist Dis, 09/25/2017. (Also see DMARDs and Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Evaluation of a patient decision aid (PtDA) for initiating disease modifying anti–rheumatic drugs. The PtDA can be a valuable aid in improving patient participation in decision–making about disease modifying anti–rheumatic drugs (DMARDs). BioMed Central, Arthritis Research & Therapy, 10/28/2016. (Also see DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction (MI) in rheumatoid arthritis. C–reactive protein (CRP) was associated with risk of MI and the results underline the importance of tight disease control taking not only global disease activity, but also CRP as an individual marker into account. Bio Med Central, Arthritis Research & Therapy, 08/05/2016. (Also see Symptoms and Complications of Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Treatment patterns and costs for anti–TNFα biologic therapy in patients with psoriatic arthritis. While the majority of patients received only one line of anti–TNFα therapy, a subset of patients switched to multiple lines of therapy during the 3–year follow-up period. BMC Musculoskeletal Disorders, 06/14/2016. (Also see Psoriasis and Psoriatic Arthritis and DMARD's) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Safety of treatments for primary Sjögren’s syndrome. Synthetic DMARDs have not shown much efficacy in earlier studies, while biologic DMARDs show promising results regarding efficacy and cause mostly mild adverse events. PubMed, Expert Opin Drug Saf, 01/25/2016. (Also see Treatments for Symptoms of Sjögren’s Syndrome and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×